173 related articles for article (PubMed ID: 30785102)
1. Unexpected Anaphylaxis After Completing a Desensitization Protocol to Oxaliplatin: Successful Adjuvant Use of Omalizumab.
Prieto-García A; Noguerado B; Rojas P; Torrado I; Rodríguez-Fernández A; Tornero P
J Investig Allergol Clin Immunol; 2019 Feb; 29(1):53-55. PubMed ID: 30785102
[No Abstract] [Full Text] [Related]
2. Successful Desensitization to Oxaliplatin After a Single Initial Dose of Omalizumab in a Patient With Elevated IgE Levels.
Penella J; Quan P; Carvallo A; Chopitea A; Sala P; García Del Barrio MA; Gastaminza G; Goikoetxea MJ
J Investig Allergol Clin Immunol; 2020; 30(4):293-295. PubMed ID: 32101174
[No Abstract] [Full Text] [Related]
3. Local peritoneal toxicity from adjuvant pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in high-risk patients with colonic cancer.
Graversen M; Detlefsen S; Pfeiffer P; B Mortensen M
Br J Surg; 2021 May; 108(5):e187-e188. PubMed ID: 33793765
[No Abstract] [Full Text] [Related]
4. Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment?
Tiotiu A; Poreaux C; Poncet P; Senechal H; Schmutz JL
Eur J Dermatol; 2019 Feb; 29(1):101-102. PubMed ID: 30734715
[No Abstract] [Full Text] [Related]
5. Omalizumab may facilitate drug desensitization in patients failing standard protocols.
Gemici Karaaslan HB; Karabag Yilmaz E; Gulmez R; Canpolat N; Kiykim A; Cokugras HC
Pediatr Allergy Immunol; 2022 May; 33(5):e13783. PubMed ID: 35616895
[No Abstract] [Full Text] [Related]
6. Treatment of idiopathic anaphylaxis with omalizumab.
Sanchez-Valenzuela MC; Garcia-Saucedo JC; Motoa G; Carrillo-Martin I; Gonzalez-Estrada A
Ann Allergy Asthma Immunol; 2019 Dec; 123(6):612-613. PubMed ID: 31568858
[No Abstract] [Full Text] [Related]
7. Usefulness of Omalizumab in Rapid Drug Desensitization in Patients With Severe Anaphylaxis Induced by Carboplatin: Open Questions.
Sánchez-Morillas L; Casado Herráez A; Rubio-Perez M; Robledo Echarren T; González Gutiérrez ML; Cimarra M; Vázquez Cortés S; Cerecedo I; Fernández-Rivas M
J Investig Allergol Clin Immunol; 2020; 30(4):298-300. PubMed ID: 32101175
[No Abstract] [Full Text] [Related]
8. Efficacy of a short pretreatment with omalizumab in children with anaphylaxis to hymenoptera venom immunotherapy: A report of three cases.
Droitcourt C; Ponvert C; Dupuy A; Scheinmann P; Abou-Taam R; de Blic J; Lezmi G
Allergol Int; 2019 Apr; 68(2):268-269. PubMed ID: 30342888
[No Abstract] [Full Text] [Related]
9. Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels.
Ojaimi S; Harnett PR; Fulcher DA
J Allergy Clin Immunol Pract; 2014; 2(1):105-6. PubMed ID: 24565780
[No Abstract] [Full Text] [Related]
10. Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a wasp sting.
Palgan K; Bartuzi Z; Gotz-Zbikowska M
Int J Immunopathol Pharmacol; 2014; 27(1):109-12. PubMed ID: 24674685
[TBL] [Abstract][Full Text] [Related]
11. [Readministration of oxaliplatin using a rapid desensitization method after severe anaphylactic reaction].
Arotçarena R; Berthélémy P; Piot M; Pariente A
Gastroenterol Clin Biol; 2001 Feb; 25(2):206-7. PubMed ID: 11319450
[No Abstract] [Full Text] [Related]
12. Successful treatment with omalizumab in challenge confirmed exercise-induced anaphylaxis.
Christensen MJ; Bindslev-Jensen C
J Allergy Clin Immunol Pract; 2017; 5(1):204-206. PubMed ID: 27839749
[No Abstract] [Full Text] [Related]
13. Anaphylaxis due to progesterone hypersensitivity successfully treated with omalizumab.
Heffler E; Fichera S; Nicolosi G; Crimi N
J Allergy Clin Immunol Pract; 2017; 5(3):852-854. PubMed ID: 28258855
[No Abstract] [Full Text] [Related]
14. Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis.
Constantine GM; Bressler PB; Petroni D; Metcalfe DD; Carter MC
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1314-1316. PubMed ID: 30149096
[No Abstract] [Full Text] [Related]
15. A case report of oxaliplatin extravasation.
Foo KF; Michael M; Toner G; Zalcberg J
Ann Oncol; 2003 Jun; 14(6):961-2. PubMed ID: 12796037
[No Abstract] [Full Text] [Related]
16. Omalizumab in children with severe allergic disease: a case series.
Crisafulli G; Caminiti L; Chiera F; Arasi S; Salzano G; Panasiti I; Barbalace A; Pajno GB
Ital J Pediatr; 2019 Jan; 45(1):13. PubMed ID: 30642367
[TBL] [Abstract][Full Text] [Related]
17. Successful administration of omalizumab by desensitization protocol following systemic reactions in 12 patients.
Bernaola M; Hamadi SA; Lynch DM; Marquis KA; Silver JN; Castells MC; Hsu JT
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2505-2508.e1. PubMed ID: 33601048
[No Abstract] [Full Text] [Related]
18. Adyuvant Use of Omalizumab in Desensitization to Chemotherapeutics: Beyond IgE-Mediated Reactions.
Prieto-García A; Rojas-Pérez-Ezquerra P; Noguerado-Mellado B; Zambrano G; Cuevas C; Juárez A; Tornero-Molina P
J Investig Allergol Clin Immunol; 2023 Dec; 33(6):497-499. PubMed ID: 37082897
[No Abstract] [Full Text] [Related]
19. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab.
Schulze J; Rose M; Zielen S
Allergy; 2007 Aug; 62(8):963-4. PubMed ID: 17484729
[No Abstract] [Full Text] [Related]
20. Combining anti-IgE with oral immunotherapy.
Lin C; Lee IT; Sampath V; Dinakar C; DeKruyff RH; Schneider LC; Nadeau KC
Pediatr Allergy Immunol; 2017 Nov; 28(7):619-627. PubMed ID: 28782296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
